文献速递淋巴瘤

个性化多肽T细胞激活剂治疗慢性淋巴细胞白血病:开放标签单中心1期研究

Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study.
PubMed 文献 · Lancet Haematol · 2026-01-14

这项在德国开展的开放标签单中心1期研究,评估了个性化仓储式多肽T细胞激活剂iTAC-XS15-CLL01联合TLR1/2配体XS15在BTKi治疗中达到部分缓解的CLL患者中的免疫原性、安全性和毒性。20例患者接受3次月度皮下注射,19例(95%)诱导出T细胞应答,末次治疗时无4级不良事件或治疗相关严重不良事件。

要点

  • iTAC-XS15-CLL01在BTKi治疗的CLL患者中诱导多肽特异性T细胞应答率达95%。
  • 常见3级不良事件为注射部位红斑(15%)、肉芽肿(10%)和溃疡(5%)。
  • 无4级不良事件、治疗相关严重不良事件或死亡,支持进一步2期评估。

核心结论

  • iTAC-XS15-CLL01可能是CLL患者有效的免疫治疗药物,应进一步开展2期试验评估。

研究设计与样本

  • 开放标签、单中心、1期研究,在德国开展,筛查30例CLL患者,20例进入治疗阶段并随访6个月。
  • 入组患者年龄≥18岁,ECOG评分≤2,HLA同种异型至少匹配肽库中一个相应HLA等位基因,且BTKi治疗6-8个月后达至少部分缓解并残留微小残留病。
  • iTAC-XS15-CLL01含8条CLL特异性肽,基于HLA分型和免疫肽组学从肽库中为患者个体化选择。
  • 患者每月接受3次iTAC-XS15-CLL01皮下注射,每次含每种肽300 μg加XS15 50 μg,以Montanide ISA 51 VG乳化。
  • 主要终点为IFNγ ELISpot评估的T细胞应答诱导(与基线比较)及从首次应用到治疗结束的不良事件频率和严重程度,所有分析按方案进行。

主要发现

  • 最常见3级不良事件为注射部位红斑(3/20,15%)、肉芽肿(2/20,10%)和溃疡(1/20,5%)。
  • 无4级不良事件、治疗相关严重不良事件或死亡。

临床怎么用

  • 对于BTKi治疗6-8个月后达部分缓解且残留微小残留病的CLL患者,个性化多肽T细胞激活剂可诱导持久T细胞应答且安全性可接受。
  • 治疗相关3级不良事件主要为局部注射部位反应,无治疗相关严重不良事件,支持进一步2期试验评估。

局限性

  • 开放标签、单中心、1期研究,样本量20例,随访6个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Therapeutic T-cell activation to induce tumour-specific immune responses promises sustainable cancer control. However, this treatment is not yet widely used because of the challenges of personalised drug design and a shortage of mutation-derived neoepitopes. This study aimed to evaluate the immunogenicity, safety, and toxicity of iTAC-XS15-CLL01, a personalised warehouse-based multipeptide T-cell activator combined with the Toll-like receptor 1/2 ligand XS15, in patients with chronic lymphocytic leukaemia who were undergoing Bruton's tyrosine kinase inhibitor (BTKi)-based regimes. METHODS: This open-label, single-centre, phase 1 study, conducted in Germany, enrolled patients aged 18 years or older who had chronic lymphocytic leukaemia with an Eastern Cooperative Oncology Group score of 2 or lower and were due to receive a BTKi-based regimen either as monotherapy or in combination (eg, with anti-CD20). The patients' HLA allotype had to match at least one of the corresponding HLA alleles of peptides included in the peptide warehouse. To begin treatment with iTAC-XS15-CLL01, patients had to have reached at least partial remission with remaining minimal residual disease after 6-8 months of BTKi therapy. iTAC-XS15-CLL01 comprised eight chronic lymphocytic leukaemia-specific peptides, selected for the individual patient from a peptide warehouse on the basis of HLA allotyping and immunopeptidomics. Participants received three monthly doses of iTAC-XS15-CLL01 (consisting of 300 μg of each peptide plus 50 μg XS15, emulsified in Montanide ISA 51 VG), injected subcutaneously. The primary endpoints were induction of a T-cell response after application of iTAC-XS15-CLL01 compared with baseline, as assessed with IFNγ ELISpot assays, and the frequency and severity of adverse events from the first application of iTAC-XS15-CLL01 to end of treatment. All analyses were done per protocol. This study was registered with ClinicalTrials.gov (NCT04688385) and is now closed. FINDINGS: Between Jan 21, 2021, and July 7, 2023, 30 patients with chronic lymphocytic leukaemia were screened, and 20 were recruited to enter the iTAC-XS15-CLL01 treatment phase and followed up for 6 months. All patients were of White ethnicity; six (30%) patients were female, and 14 (70%) were male. Median age was 56·5 years (IQR 49·5-65·5). The most common grade 3 adverse events were injection-site erythema (three [15%] of 20 patients), granuloma (two [10%] of 20), and ulceration (one [5%] of 20). There were no grade 4 adverse events, treatment-related serious adverse events, or deaths. T-cell responses targeting multiple peptides were induced in 19 (95% [95% CI 75·1-99·9]) of 20 patients at end of treatment and persisted in 16 (84%) of 19 at 6 months follow-up, with the intensity of responses increasing until end of study. INTERPRETATION: Our findings indicate that iTAC-XS15-CLL01 could be a potent immunotherapeutic agent in patients with chronic lymphocytic leukaemia and should be further evaluated in phase 2 trials. FUNDING: Medical Faculty, Tübingen University.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Heitmann JS, Maringer Y, Jung S, et al. Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study. Lancet Haematol. 2026. PMID: 41547362. doi:10.1016/S2352-3026(25)00323-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。